We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adient's (ADNT) Q3 Earnings Miss Estimates, Revenues Up
Read MoreHide Full Article
Adient plc (ADNT - Free Report) reported third-quarter fiscal 2018 earnings per share of $1.45, lagging the Zacks Consensus Estimate of $1.56. The bottom-line figure in the year-ago quarter was $2.49 per share.
During the quarter under review, the company reported net sales of $4.5 billion, up 12% from that of third-quarter fiscal 2017. Also, the top line beat the Zacks Consensus Estimate of $4.3 billion. During the reported quarter, gains generated from Futuris acquisition, China JV consolidation and foreign exchange positive aided revenue growth.
During the quarter under review, net income attributed to Adient was $54 million compared with the net income of $201 million in third-quarter fiscal 2017.
During the reported quarter, the Seating segment of the company reported net sales of $4 billion, up from $3.6 billion in third-quarter fiscal 2017.
Adjusted EBITDA of this segment amounted to $344 million, down from $413 million in third-quarter fiscal 2017.
The Seat Structures & Mechanisms (“SS&M”) segment reported revenues of $783 million, up from $713 million in the prior-year quarter. Adjusted EBITDA of this segment amounted to negative $26 million compared with a negative $39 million in third-quarter fiscal 2017.
Financials
Adient had cash and cash equivalents of $378 million as of Jun 30, 2018, compared with $709 million as of Sep 30, 2017.
As of the same date, net debt amounted to $3.1 billion, up from $2.8 billion as of Sep 30, 2017.
Fiscal 2018 Outlook
For fiscal 2018, the company anticipates revenues of around $17.5 billion, up from the prior guidance of $17-$17.2 billion. Adjusted EBITDA is likely to be around $1.25 billion, down from the earlier guidance of $1.40-$1.45 billion.
Zacks Rank & Key Picks
Currently, Adient has a Zacks Rank #5 (Strong Sell).
Oshkosh has an expected long-term growth rate of 18.3%. Over the past year, shares of the company have moved up 7.3%.
AB Volvo has an expected long-term growth rate of 15%. Over the past year, shares of the company have gained 2.3%.
Fox Factory has an expected long-term growth rate of 15.8%. Shares of the company have risen 30.2% over the past year.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Adient's (ADNT) Q3 Earnings Miss Estimates, Revenues Up
Adient plc (ADNT - Free Report) reported third-quarter fiscal 2018 earnings per share of $1.45, lagging the Zacks Consensus Estimate of $1.56. The bottom-line figure in the year-ago quarter was $2.49 per share.
During the quarter under review, the company reported net sales of $4.5 billion, up 12% from that of third-quarter fiscal 2017. Also, the top line beat the Zacks Consensus Estimate of $4.3 billion. During the reported quarter, gains generated from Futuris acquisition, China JV consolidation and foreign exchange positive aided revenue growth.
During the quarter under review, net income attributed to Adient was $54 million compared with the net income of $201 million in third-quarter fiscal 2017.
Adient PLC Price, Consensus and EPS Surprise
Adient PLC Price, Consensus and EPS Surprise | Adient PLC Quote
Quarter in Details
During the reported quarter, the Seating segment of the company reported net sales of $4 billion, up from $3.6 billion in third-quarter fiscal 2017.
Adjusted EBITDA of this segment amounted to $344 million, down from $413 million in third-quarter fiscal 2017.
The Seat Structures & Mechanisms (“SS&M”) segment reported revenues of $783 million, up from $713 million in the prior-year quarter. Adjusted EBITDA of this segment amounted to negative $26 million compared with a negative $39 million in third-quarter fiscal 2017.
Financials
Adient had cash and cash equivalents of $378 million as of Jun 30, 2018, compared with $709 million as of Sep 30, 2017.
As of the same date, net debt amounted to $3.1 billion, up from $2.8 billion as of Sep 30, 2017.
Fiscal 2018 Outlook
For fiscal 2018, the company anticipates revenues of around $17.5 billion, up from the prior guidance of $17-$17.2 billion. Adjusted EBITDA is likely to be around $1.25 billion, down from the earlier guidance of $1.40-$1.45 billion.
Zacks Rank & Key Picks
Currently, Adient has a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the auto space are Oshkosh Corporation (OSK - Free Report) , AB Volvo (VLVLY - Free Report) and Fox Factory Holding Corp. (FOXF - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Oshkosh has an expected long-term growth rate of 18.3%. Over the past year, shares of the company have moved up 7.3%.
AB Volvo has an expected long-term growth rate of 15%. Over the past year, shares of the company have gained 2.3%.
Fox Factory has an expected long-term growth rate of 15.8%. Shares of the company have risen 30.2% over the past year.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>